The Raf/MEK/MAP kinase cascade plays a critical role in transducing growth signals from activated cell surface receptors. Using ⌬MEK1:ER, a conditionally active form of MEK1, we demonstrate the ability of this dual specificity protein kinase to abrogate the cytokine dependency of the murine lymphoid hematopoietic cell line FL5.12. Cytokine-independent cells were obtained from FL5.12 cells at a frequency of 1 × 10 −7 , indicating that a low frequency of cells expressing ⌬MEK1:ER were factor-independent. In general, cells that were converted to a cytokine-independent phenotype displayed a higher level of MAP kinase activity in response to ⌬MEK1:ER activation than those that remained cytokine-dependent. ⌬MEK1:ER-responsive cells could be maintained long-term in the presence of ␤- 
Introduction
The proliferation of many hematopoietic precursor cells is promoted by interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell factor (SCF), flt-3L (the ligand for the tyrosine kinase receptors flt-2 and flt-3), thrombopoietin and certain other cytokines. [1] [2] [3] Hematopoietic cell lines have been isolated which require IL-3 or in some cases GM-CSF for survival and cell proliferation. [4] [5] [6] The murine FL5.12 cell line is an IL-3-dependent cell line isolated from murine fetal liver that is representative of early lymphoid progenitor cells. 5 Cytokine deprivation of these cells results in rapid cessation of growth with subsequent death by apoptosis (programmed cell death). 2, 3, 7, 8 In the presence of IL-3, these cells proliferate continuously, however, they are nontumorigenic when injected into immunocompromised mice. 6, 7, [9] [10] [11] [12] Spontaneous factor-independent cells are rarely recovered from the FL5.12 cell line which makes them an attractive model to analyze the effects that various genes have on signal transduction and leukemogenesis, since abrogation of cytokine dependency may be an important factor in the development of leukemia. 7, [10] [11] [12] [13] [14] IL-3 and GM-CSF exert their biological activity by binding to the IL-3 and GM-CSF receptors, respectively. These receptors are comprised of a ligand-specific ␣-subunit and a common ␤-subunit (␤ c ) which is essential for signal transduction. 3, [15] [16] [17] [18] [19] [20] The binding of these cytokines to their cognate receptors activates Janus (Jak) protein tyrosine kinases which lead to the phosphorylation and dimerization of signal transducers and activators of transcription (STAT). Activated STAT proteins then regulate the expression of key genes involved in cell growth. 3, 18, 21 The activation of Jak2 by IL-3 may occur by receptor aggregation resulting in the multimerization of associated Jak2 proteins. 18 Upon receptor ligation, a complex, consisting of Cbl/Grb2/Sos and the guanidine nucleotideexchange factor Vav, is recruited to the ␤ c chain by tyrosine phosphorylated Shc. [22] [23] [24] [25] The receptor-associated complex results in the stimulation of Ras, as well as additional signal transduction molecules such as PI3 kinase and potentially members of the Src-family of tyrosine kinases. 26, 27 Activated Ras promotes the sequential activation of Raf, MEK and MAP kinases. [28] [29] [30] [31] Recently, it was shown that Jak1 can directly activate Raf indicating cross-talk capability between these two signal transduction pathways. [32] [33] [34] Evidence suggests that the Ras/Raf/MEK/MAPK pathway is intimately associated with the control of cell growth, differentiation and apoptotic machinery in myelo-monocytic cells. 19, 27, [35] [36] [37] Constitutively activated forms of MEK1 have been described that transform NIH-3T3 cells. Either deletion of the N-terminal negative regulatory domain, which contains the nuclear export signal (NES), or substitution of serine with aspartic acid and/or glutamic acid at two critical phosphorylation sites results in an activated MEK1 oncoprotein. [38] [39] [40] [41] MEK1 expression can lead to activation of the MAP kinases, ERK1 and ERK2. These protein kinases have pleotropic effects on the cell, but likely elicit some of their effects by the phosphorylation of transcription factors that control gene expression. 37, 42 Abrogation of cytokine dependency requires the prevention of apoptosis. Hence, in addition to promoting cell cycle progression, cytokines must affect the machinery that controls cell survival. Apoptosis is strongly influenced by the activity of BCL2 and its family members. [43] [44] [45] [46] [47] [48] Both BCL2 and BCL-X L promote cell survival, whereas BAX and BAD promote cell death. 43, 44 Although the precise details of how cytokines influence the function of these proteins are not fully elucidated, recent evidence has suggested that protein expression, subcellular localization and phosphorylation leading to the control of protein-protein interactions may be central to the process. [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] Moreover, the Ras/Raf/MEK/ERK kinase pathway can suppress apoptosis in cytokine-dependent cells. 19, 45, 55 The role(s) of MEK1 in the apoptotic pathways is not clear. However, some studies with PC 12 neuronal cells have shown that c-Jun N-terminal Kinase (JNK) and MEK1 have opposing effects on apoptosis with JNK promoting and MEK1 inhibiting programmed cell death. 56 It has been reported that activated MEK1 failed to relieve the IL-3 dependency of the BAF/3 lymphoid cell line. 57 However, given the pivotal role of MEK1 in the MAP kinase cascade, we decided to investigate the ability of activated MEK1 to abrogate the cytokine dependency of other cytokine dependent human and murine cell lines. Previous studies in TF-1 and FDC-P1 cells, which are representative of myeloid precursors, found that a conditionally active form of MEK1, ⌬MEK1:ER, could relieve the cytokine dependence of a subset of these cells. MEK1-responsive TF-1 and FDC-P1 cells were recovered at a frequency of 2.5 × 10 −3 and 5 × 10 −5 , respectively. 58 These MEK1-responsive cells were found to express autocrine GM-CSF at sufficient levels to promote cell proliferation. In this study, the effects this conditionally active form of MEK1 had on the cytokine dependency of FL5.12 hematopoietic cells were examined. We demonstrate the ability of activated MEK1 to convert a small subset of FL5.12 cells to a cytokine-independent phenotype. ⌬MEK1:ER induced ERK2 activity with higher levels detected in MEK1-responsive as compared to cytokine-dependent ⌬MEK1:ER-infected cells. In addition, ⌬MEK1:ER induced GM-CSF mRNA accumulation which contributed to an autocrine proliferation loop in these cells. Moreover, alterations in GM-CSFR expression were discovered between the cytokine-dependent and MEK1-responsive FL5.12 cells. Understanding the molecular mechanisms of these effects will further our comprehension of the role the MEK/MAP kinase pathway plays in the control of both normal and aberrant cell proliferation.
Materials and methods

Cell lines and growth factors
Cells were maintained in a humidified 5% CO 2 incubator. The IL-3-dependent lymphoid cell line FL5.12 5 were cultured in RPMI 1640 medium (RPMI; Life Technologies, Rockville, MD, USA) supplemented with 10% WEHI-3B(D − ) conditioned medium (WCM) as a source of murine IL-3, and 5% iron-supplemented bovine calf serum (BCS; Hyclone, Logan, UT, USA). Estradiol-dependent ⌬MEK1:ER (MEK1-responsive) cells were grown in RPMI + 5% FCS + 1 M ␤-estradiol (Sigma, St Louis, MO, USA). ⌬MEK1:ER-infected cells were in some cases cultured in 4-OH Tamoxifen (4-HT) (Sigma), an estrogen analog which is an activator of the ⌬MEK1:ER fusion protein.
59 ⌬MEK1:ER-infected cells were in some cases treated with the phorbol ester, phorbol 12-myristate 13-acetate (PMA) (Sigma). These chemicals were dissolved in either dimethyl sulfoxide (DMSO, Sigma) (PMA) or ethanol (4-HT). The ␣-murine IL-3 and GM-CSF neutralizing antibodies were purchased from R&D systems (Minneapolis, MN, USA). The ␣-human insulin-like growth factor-1 receptor (IGF-1R) was purchased from Calbiochem (San Diego, CA, USA). Aphidocolin and nocadazole were purchased from Calbiochem and used at 5 g/ml and 0.1 g/ml, respectively. ]-thymidine (6.7 Ci/mmol; NEN, Boston, MA, USA) which was added during the last 4-6 h of culture as described. 5, 7, 9 Retroviral infection of cells Cells were infected with a retrovirus (pBabepuro3) 60 encoding a fusion protein (⌬MEK1:ER) between a constitutively activated form of MEK1 (⌬N3-S218E-S222D) and the hormonebinding domain of the human estrogen-receptor (hbER) as described previously for Raf-1. 39, 59, [61] [62] [63] This retrovirus also encodes resistance to the antibiotic puromycin (puro r ). Plasmid DNAs containing recombinant retroviruses were transfected into the retroviral packaging cell lines PA317 and 2 using lipofectin (Life Technologies, Bethesda, MD, USA). Retroviruses were passed sequentially from one cell line to the other to amplify their titers as described previously. 9 Puro r PA317 and 2 cells were isolated by selection in Dulbecco's modified Eagle's medium (DMEM) + BCS and 2 g/ml puromycin (Sigma). Puromycin-resistant (puro r ) FL5.12 cells were isolated by selection in 2 g/ml puromycin in the presence of either IL-3 or ␤-estradiol. The nomenclature of the FL5.12 cells is FL/⌬MEK1:ER for cells infected with the ⌬MEK1:ER virus. (IL3) indicates that the FL5.12 cells were selected in IL-3, and (Est) indicates that the FL5.12 cells were selected in ␤-estradiol. These symbols are followed by either (pool) for a pool of cells or (c) for a clone.
Preparation of cell extracts and analysis by Western blotting
Cells were washed twice with cold phosphate-buffered saline (PBS) containing 5 mM Na 2 EDTA and lysed on ice in gold lysis buffer (GLB) containing 20 mM Tris (pH 7.5), 137 mM NaCl, 5 mM Na 2 EDTA, 1% (v/v) Triton X-100, 15% (v/v) glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM sodium orthovanadate, 1 mM ethylene glycol-bis (␤-aminoethyl ether)-N,N,NЈ,NЈtetraacetic acid (EGTA), 10 mM sodium fluoride, 1 mM tetrasodium PP i , and 100 M ␤-glycerophosphate. Insoluble material was removed by centrifugation at 15 000 g as described.
8,59,61-63 All chemicals were purchased from Sigma unless otherwise indicated. The protein concentration of the soluble material was estimated as described previously. 8, 59, [61] [62] [63] 
Determination of MEK1 activity
Lysates were prepared from cells cultured in phenol-red free DMEM or RPMI medium (Life Technologies or Sigma, respectively) containing charcoal-stripped BCS as described above. Some cells were treated with ␤-estradiol. The WEHI-3B supernatant used in these studies (as a source of IL-3) was prepared from cells grown in phenol red-free DMEM medium containing charcoal-stripped BCS. MEK activity was measured by immunoprecipitating 100 g of total protein lysate overnight with an ␣ER Ab or ␣MEK1 Ab and protein A-sepharose beads. Ci/mmol) and 2 g of bacterially expressed rp44, an enzymatically inactive form of MAP kinase (ERK1). The reactions were stopped by adding 7.5 l of protein sample buffer and boiling for 3 min. The reaction mixtures were electrophoresed through a 10% polyacrylamide gel, transferred to polyvinylidene difluoride (PVDF; Millipore, New Bedford, MA, USA) and exposed to X-ray film.
Determination of MAP kinase activity
Cells were deprived of either cytokine or ␤-estradiol for 18-24 h in phenol-red free medium that contained 5% charcoalstripped BCS. The cells were then pulsed with cytokine, ␤-estradiol or the positive control, 20 nM PMA for varying periods of time. ERK2 activity was determined using an in vitro kinase assay. An ␣ERK2 Ab (SCB) and protein A-sepharose beads were used to immunoprecipitate the ERK2 protein overnight from 100 g of total protein lysate. The immunoprecipitates were washed and then used in a kinase reaction containing 43 mM Hepes pH 7.4, 43 mM MgCl 2 , 200 M ATP, 0.5 mM DTT, 1 M [␥-
32 P]-ATP and 2.3 g myelin basic protein (MBP, Life Technologies) as a substrate. The reactions were carried out at 30°C for 30 min before being stopped with 7.5 l of sample buffer and boiling for 3 min. The reaction mixtures were electrophoresed through a 14% polyacrylamide gel, transferred to PVDF and exposed to X-ray film.
Analysis of cell cycle distribution
Cells were incubated at approximately 2 × 10 5 cells/ml in 25 ml of phenol-red free RPMI (Sigma) containing stripped BCS (Fisher) lacking cytokine or ␤-estradiol but in some cases containing either the G 1 inhibitor amphidicolin (5 g/ml) or the G 2 /M inhibitor nocadozole (0.1 g/ml). This initial time point was designated (−24 h). Twenty-four hours later at the T 0 point, the cell cycle inhibitors were remove if present in the media and either IL-3 (10%) or 4-HT (250 nM) was added to the cultures. Aliquots of approximately 1 × 10 6 cells (3-4 ml) were subsequently removed at 12-h intervals starting at the −24 h point. Aliquots were centrifuged and supernatants were removed by aspiration. Cell pellets prepared from the different incubation times and culture conditions were washed once in 1 ml of phosphate buffered saline (PBS), centrifuged as before, and the wash was then removed by aspiration. The cell pellets were resuspended in 0.5 ml of PBS and then fixed and permeabilized by the addition of 4.5 ml of 70% ethanol. The cells were fixed overnight at 4°C. The next day, the cells were collected by centrifugation as before and washed once with PBS containing 1% bovine serum albumine (BSA). The cell pellets were resuspended in 0.5 ml of solution containing propidium iodide (50 g/ml), RNase (240 g/ml; Sigma) and Triton X-100 (0.01% v/v; Sigma). Cells were stained for 30 min in the dark. The cell suspensions were passed through a 25-gauge needle once before cell cycle analysis. The percentage of cells in the various phases of the cell cycle was acquired on a Becton Dickinson FACS analyzer (Bedford, MA, USA). The percentage of cells in the different phases of the cell cycle was statistically analyzed using the Modfit 5.02 program.
Isolation of low molecular weight DNA for apoptosis assays
Cells (4 × 10 5 cells/ml) were grown in phenol-red free DMEM in the absence of cytokine or ␤-estradiol or in the presence of either cytokine or ␤-estradiol for 1 day. The cells were pelleted by centrifugation. The supernatants were discarded. The pellets were resuspended in 500 l of apoptosis lysis buffer (20 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.2% Triton X-100), transferred to 1.5 ml microfuge tubes and placed on ice for 10 min. The lysates were then centrifuged for 10 min at 16 000 g in order to remove all intact genomic DNA and cell debris. The supernatants were transferred to 1.5 ml microfuge tubes while the pellets were discarded. Protease K (Sigma; 25 l of 4 mg/ml) was added to the supernatants, and the mixtures were incubated overnight at room temperature. The solutions were phenol extracted twice by the addition of 0.5 ml of cold phenol. The samples were then vortexed and centrifuged for 5 min at 16 000 g. The upper aqueous phase was removed and transferred to 1.5 ml microfuge tubes. The phenol extractions were followed by chloroform extractions once using 0.5 ml cold chloroform:isoamyl alcohol (25:1). The chloroform extractions were performed in the same manner as the phenol extractions. The aqueous phase was transferred to 1.5 ml microfuge tubes. The nucleic acids were ethanol precipitated by the addition of one-tenth the volume of 3 M sodium acetate and 1 ml 100% cold ethanol. The tubes were placed at −20°C overnight. The following day the nucleic acids were pelleted by centrifugation at 16 000 g. Subsequently, the precipitates were resuspended in 100 l of dH 2 O. The concentrations of the nucleic acids were determined on aliquots by optical density readings. Nucleic acid (40 g) was aliquoted to 1.5 ml microfuge tubes and lyophilized. The lyophilized pellets were gently resuspended in 15 l of 1 × DNA loading buffer containing 0.1 mg/ml RNase A (Sigma). The samples were incubated at 37°C for 5-10 min prior to loading on 1.5% agarose gels. Low molecular weight DNA was visualized with ethidium bromide. Gels were photographed over a UV light box.
Annexin V apoptosis assays
Approximately 1 × 10 7 exponentially growing MEK1-responsive and cytokine-dependent cells were collected by centrifugation. The cells were washed, incubated at approximately 2 × 10 5 cells/ml in 15 ml of phenol-red free RPMI (Sigma) containing either cytokine, ␤-estradiol or no supplement. Treated cells were collected in 3 ml aliquots after 24-72 h. The cells were transferred to 12 × 75 mm tubes and centrifuged at 800 g for 5 min at 4°C. The supernatants were removed by aspiration, and the cell pellets were resuspended in 1 ml PBS. The cells were then centrifuged as before, and the supernatants were again aspirated. Following a second wash in PBS, the cells were stained with 100 l of Annexin V (Roche Diagnostics, Indianapolis, IN, USA; 1 g/ml in Annexin V binding buffer (50 mM HEPES, pH 7.5, 125 mM NaCl, 2.5 mM CaCl 2 )). The cells were allowed to incubate with Annexin V for 30 min at RT in the dark. After incubation, the cells were centrifuged as before, and the Annexin V solution was removed by aspiration. The cells were washed once as before in 1 ml of PBS. Following the removal of the PBS wash, the cells were resuspended in 100 l of propidium iodide (PI) solution (Boehringer, Mannheim, Germany; 10 g/ml in Annexin V binding buffer) and incubated in the dark for 30 min at RT. Annexin V binding buffer (0.7 ml) was added directly to the samples prior to analyzing on a Becton Dickinson FACs analyzer. Controls, which were unstained, stained with Annexin V only, or stained with PI only, were used to calibrate the FACs analyzer for each experiment.
Polymerase chain reaction amplification of cytokine mRNA transcripts
Total cytoplasmic RNA was prepared as described.
8,9,64 1 g was included in a 20 l cDNA synthesis reaction containing: reverse transcriptase buffer, 1 mM of each dNTP, 20 mg/ml oligo-dT and 20 units Mo-MuLV reverse transcriptase. After incubation at 42°C for 40 min, the reaction was terminated by addition of H 2 0. For PCR amplification, 5 l cDNA was included in a 50 l reaction mixture containing PCR buffer, dNTP, 1-2 units Taq polymerase and 1 mM of each oligonucleotide primer. The primers for murine IL-3 were: AAT-CAGTGGCCGGGATACCC and CGAAATCATCCAGATCTCG defining a 200 bp cDNA fragment which could readily be distinguished from a genomic IL-3 DNA fragment by size (Ͼ1 kb). The primers for murine GM-CSF were: CCTGAGGAG GATGTGGCTGC and CTGTCCAAGCTGAGTCAGCG defining a 601 bp fragment. The primers for murine ␤ 2 -microglobulin were TTCTCTCACTGACCGGCCTG and CAGTAGACGG TCTTGGGCTC defining a 308 bp fragment. Thirty-five cycles of PCR were performed to detect the cDNAs. The PCR products were electrophoresed on 1% agarose gels and visualized after ethidium bromide staining of the gel. Bands that were the expected size were verified by performing Southern hybridization using the appropriate full-length cDNA probe.
Detection of IL-3/GM-CSF receptor expression on FL5.12 cells
The expression of IL-3 and GM-CSF receptors was measured in MEK1-responsive and cytokine-dependent FDC-P1 and FL5.12 cells. Approximately 1 × 10 7 exponentially growing cells were collected by centrifugation at 800 g for 5 min. The cells were washed three times with PBS, collected after each wash as described, and then incubated at approximately 1 × 10 6 cells/ml in 5 ml of phenol-red free RPMI (Sigma) containing either IL-3, ␤-estradiol, IL-3 and ␤-estradiol or no supplement. After culturing for 24 h, the cells were transferred to 12 × 75 mm tubes and centrifuged at 800 g for 5 min. The supernatants were aspirated off. The cells were then washed twice in PBS and collected each time by centrifugation as before. After the final wash was aspirated, the cell pellets were resuspended in 100 l of primary antibody (1:100 dilution of anti-IL-3R␣ (SCB), anti-GM-CSFR␣ (SCB), anti-IL-3R␤ IL-3 or anti-␤ c in PBS) and incubated on ice for 30 min. The anti-IL-3R␤ IL-3 and anti-␤ c were provided by Dr A Miyajima (DNAX, Palo Alto, CA, USA). Once the incubation was complete, 1 ml of PBS was added to each sample and gently mixed. The samples were again centrifuged, and the supernatants were aspirated. The cell pellets were resuspended in 100 l of secondary antibody (1:10 dilution of FITC conjugated goat antirat (Sigma; anti-IL-3R␤ IL-3 and anti-␤ c ) or FITC conjugated goat anti-rabbit (Sigma; anti-IL-3R␣ and anti-GM-CSFR␣) and incubated for 30 min on ice in the dark. After 30 min, 1 ml of PBS was added to each sample and gently mixed. The samples were centrifuged as before, and the supernatants were aspirated. The cell pellets were gently resuspended in 1 ml of PBS and analysed on a Becton Dickinson FACs analyzer. Controls Leukemia for these experiments consisted of treated and untreated cells that were only incubated with the FITC conjugated secondary antibody.
MTT viability assays
The viability of cells under various culture conditions was accessed by measuring the ability of the cells to cleave the soluble compound 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma) into an insoluble salt. The ability of cells to cleave MTT is indicative of the degree of mitochondrial/cellular respiration within those cells. Cells (1 × 10 6 /96-well plate) were seeded into wells which contained 1:3 serial dilutions of IL-3 or GM-CSF. The cells were cultured for 1-3 days. On the day to be assayed, 10 l of 5 mg/ml MTT was added to each well of the 96-well plate. The cells were cultured for 4 h in the presence of MTT. The culture media was then removed by pipetting, being careful not to resuspend any cells. DMSO (100 l) was added to each well to solubilize the colorimetric salt. The plates were then read on an spectrophotometric plate reader at 570 nm wavelength.
Results
Aberrant MEK1 activation can abrogate the cytokine dependency of hematopoietic cells
It was shown previously that constitutively active forms of MEK1 can transform NIH-3T3 and Chinese hamster ovary (CHO) fibroblast cells in culture. [38] [39] [40] [41] We wished to determine the effects of a conditionally active form of MEK1 on cells that require the presence of cytokines for proliferation. The following studies have utilized a conditionally active form of MEK1 generated by the fusion of sequences encoding a constitutively-active form of MEK1 (⌬N3-S218E-S222D) to the hormone-binding domain of the human estrogen-receptor in a manner analogous to that described previously for Raf. 8, 59, [61] [62] [63] FL5.12 cells were infected with a retrovirus encoding ⌬MEK1:ER or an empty vector encoding only puromycin resistance (puro r ). Infected cells were subsequently selected in growth medium containing puromycin in the presence of either IL-3 or ␤-estradiol. Pools of puro r FL5.12 cells were recovered from both selection conditions and expanded from 96-well plates after approximately 2 weeks in culture. Thus, infection with the ⌬MEK1:ER encoding retrovirus allowed some FL5.12 cells to grow in medium lacking exogenous IL-3. While empty retroviral vector infected puro r cells were recovered in medium containing IL-3 and puromycin, no empty retroviral vector infected cells were recovered in medium containing ␤-estradiol and puromycin. In addition, no colonies were obtained from mock-infected FL5.12 cells cultured under either selection condition. Thus, an activated MEK1 gene was necessary to abrogate the cytokine dependency of FL5.12 cells.
To determine the efficiency of abrogation of cytokine dependency of FL5.12 cells by the ⌬MEK1:ER oncoprotein, limiting dilution analysis was performed. The data were derived from the Poisson analysis of three different ⌬MEK1:ER-infected pools isolated from each of the three different cell lines. The intersections of the 37% wells negative for growth with the experimental plating ratio and the X-axis provides an estimate of the cloning efficiency. Retroviral Leukemia stocks contained approximately 10 6 puro r retroviruses/ml. pBP3puro is a puro r retroviral vector which lacks an oncogene. 60 When the FL/⌬MEK1:ER pool of cells, which had been isolated in IL-3 and puromycin (FL/⌬MEK1:ER(IL3)pool), was cultured in the presence of IL-3, a plating efficiency of approximately 1 was observed, ie every cell gave rise to a clone. In contrast, when the cells were cultured in the absence of IL-3 but in the presence of ␤-estradiol, approximately 1 in 1 × 10 7 cells gave rise to a clone (an efficiency of 1 × 10 −7 ). Thus, there was a large difference in the plating efficiency of the cells in IL-3 vs ␤-estradiol. Similar experiments were performed with the empty vector pBabepuro-infected FL5.12 cells; however, no cytokine-independent cells were recovered upon limiting dilution analysis of these empty vectorinfected cells.
Growth characteristics of FL/⌬MEK1:ER cells
The growth characteristics of the cytokine-dependent andindependent ⌬MEK1:ER-infected FL5.12 cells were examined in four clones isolated from each selection condition. ⌬MEK1:ER-infected FL5.12 cells which were isolated in IL-3 grew only in the presence of IL-3 whereas those ⌬MEK1:ERinfected FL5.12 cells which were isolated in ␤-estradiol grew in the presence of both IL-3 and ␤-estradiol (Figure 1a, c, e) . Cells which were MEK1-responsive were viable in the presence of both IL-3 and ␤-estradiol, but were not viable in the absence of both IL-3 and ␤-estradiol indicating that the cells had not acquired cytokine independence as a result of an unrelated genetic event. Cytokine-dependent FL5.12 and 
Activation of the MAP kinase pathway in response to
⌬MEK1:ER
To determine whether the presence of the ⌬MEK1:ER protein led to increased MEK1 activity in ⌬MEK1:ER-infected cells, kinase assays were performed in FL/⌬MEK1:ER cells ( Figure  2 ). These MEK assays were performed with ␣ER-immunoprecipitated ⌬MEK1:ER proteins, thus endogenous MEK1 activity was not detected. In the case of the FL5.12 parental cell line, MEK assays were performed using ␣MEK1-immunoprecipitated protein.
The cells were cultured for 24 h in medium containing 5% serum only or supplemented with cytokine, cytokine and ␤-estradiol or ␤-estradiol. The level of MEK1 activity in the FL/⌬MEK1:ER cells varied greatly in response to the different treatments (Figure 2a-c) . Cells that were treated for 24 h in the absence of cytokine and ␤-estradiol showed low levels of MEK1 activity with the MEK1-responsive clone still possessing the most MEK1 activtiy (Figure 2a-c, lanes 1) . The activity of the FL5.12 cells responded to the treatments of cytokine and cytokine and ␤-estradiol (Figure 2a , lanes 2 and 3) but did not respond significantly to ␤-estradiol alone. In contrast, the FL/⌬MEK1:ER(IL3)Pool 2 cells and FL/⌬MEK1:ER(Est)c1 cells responded with slightly higher levels of MEK1 activity in response to cytokine but showed the most significant increases in MEK1 activity in response to cytokine and ␤-estradiol or ␤-estradiol alone (Figure 2b and c, lanes 2-4) . As a loading control the level of the ⌬MEK1:ER protein in each immunoprecipitate was determined using an ␣ER antibody. As can be seen in the panels below the kinase assays, there is a slight increase in the amount of the ⌬MEK1:ER fusion protein in the immunoprecipitates in the presence of IL-3 and ␤-estradiol. This is believed to be as a result of stabilization of the ⌬MEK1:ER fusion protein under these conditions. In addition, a band seen in the parental FL5.12 cells corresponds to an upper band present in the FL5.12 cells infected with the ⌬MEK1:ER fusion protein. This band represents endogenous estrogen receptor expressed in these cells. These data indicated that treatment of the FL/⌬MEK1:ER(IL3)Pool 2 cells and FL/⌬MEK1:ER(Est)c1 cells with ␤-estradiol resulted in a significant increase in MEK1 activity in these cells.
MEK1 activates ERK2 in ⌬MEK1:ER-infected FL5.12 cells
Two of the downstream substrates of MEK1 are the MAP kinases (ERK1 and ERK2). The ability of ⌬MEK1:ER to activate ERK2 was examined in cytokine-dependent and cytokineindependent FL/⌬MEK1:ER cells. Prior to treatment, the cells were deprived of cytokine for 24 h and then treated with cytokine, ␤-estradiol or, in some cases, PMA. In all cells examined, cytokine and PMA lead to the rapid activation (15-30 min) of ERK2 ( Figure 3 ). In contrast, not all the cells examined had increased ERK2 activity in response to ␤-estradiol. The parental cell control (FL5.12) (Figure 3a ) displayed very low ERK2 activity in response to ␤-estradiol with a transient peak in activity at 15 min possibly a result of activating endogenous estrogen receptors.
In contrast, the cytokine-dependent FL/⌬MEK1:ER(IL3)pool cells (Figures 3b), as well as the cytokine-independent FL/⌬MEK1:ER(Est)c1 cells (Figures 3c), showed increased ERK2 activity in response to ␤-estradiol. ERK2 activation in response to ␤-estradiol was slightly augmented in these cells with initial activity appearing as early as 5 min and peaking between 15 and 30 min. A second peak in activity was observed approximately 2-4 h after treatment and decreased by 8 h. A third increase in ERK2 activity was seen in the MEK1-responsive cells at 10 h. and lasted up to 24 h. As a loading control these assays were western blotted with ␣ERK2 antibody. As can be seen there are no significant differences in the levels of ERK2 immunoprecipitated at the different time points from these cells. These results indicate that activation of ⌬MEK1:ER can result in MAP kinase activation and suggest the possibility of an autocrine stimulatory loop.
Leukemia
Effects of ⌬MEK1:ER on cell cycle progression
In order for MEK1 to promote cell proliferation, it must stimulate the entry and completion of the cell cycle. Therefore, the effect of MEK1 activation on cell cycle progression was examined in the FL/⌬MEK1:ER cells (Figure 4 . The cytokine-dependent FL5.12 cells were only able to re-enter the cell cycle in the presence of IL-3 with approximately 50% of the cells in S phase (Figure 4b and e) . In contrast, the FL/⌬MEK1:ER(Est)c1 cells were able to re-enter the cell cycle in response to both IL-3 and ␤-estradiol (Figure 4h ). The MEK1-responsive cells entered the cell cycle more readily to IL-3 than to ␤-estradiol as it took 48 h of ␤-estradiol stimulation to reach the same percentage of cells in S phase that was stimulated in response to IL-3 in the first 24 h. Although the response to ␤-estradiol appears to be slower in the MEK1-responsive FL5.12 cells as compared to the MEK1-responsive FDC-P1 cells (data not shown), these cells appear to be able to pass a checkpoint in cell cycle progression, the entrance into S phase, which the cytokine-dependent FL5.12 cells cannot.
In addition, due to the large percentage of cells which could not be synchronized into G1 by cytokine starvation, the effects of ⌬MEK1:ER activation on cell cycle progression were also examined in the FL/⌬MEK1:ER cells using an inhibitor/release synchronization method (data not shown). Treatment of FL/⌬MEK1:ER(Est) cells with the G1 inhibitor aphidicolin for 24 h resulted in 75% of the cells accumulating in the G1 phase (data not shown). Upon removal of the inhibitor and addition of IL-3 or 4-HT these cells exited G1 and entered the S and G2/M phases (data not shown). In contrast aphidicolin treated FL/⌬MEK1:ER(Est) cells that did not receive either IL-3 or ␤-estradiol did not leave the G1 phase or enter the S and G2/M phases as efficiently as the 4-HT-treated cells. Treatment of FL/⌬MEK1:ER(Est) cells with the G2 inhibitor nocadozole resulted in 75% of the cells leaving G1 and S phases and arresting in G2/M (data not shown). Upon removal of the inhibitor and addition of either 4-HT or IL-3 the cells entered the G1 and S phases. In contrast, treatment and release of the
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Figure 3
Effects of ⌬MEK1:ER on ERK2 activity in FL/⌬MEK1:ER cells. All the cells were cultured in the absence of IL-3 and ␤-estradiol for 24 h, and then the cells were treated for various times under the indicated conditions prior to collection of lysates. ERK2 was immunoprecipitated using an anti-ERK2 Ab. The immunoprecipitate was then assayed for its ability to phosphorylate MBP as a substrate in an in vitro kinase reaction. (a) FL5.12, (b) FL/⌬MEK1:ER(IL3)Pool 1 and (c) FL/⌬MEK1:ER(Est)c1. In addition, as a control for sample loading as well as the amount of immunoprecipitated ERK2 used in each assay, the membranes from the ERK2 kinase assays were western blotted with anti-ERK2 Ab. parental FL5.12 and cytokine-dependent FL/⌬MEK1:ER(IL3) cells with nocadozole or aphidicolin resulted in a failure to re-enter the cell cycle after stimulation with 4-HT, but not IL-3 (data not shown). Thus the cytokine-dependent and MEK1-responsive cells varied in their ability to re-enter the cell cycle after treatment of the cells with cell cycle inhibitors. This may be due to the fact that the ⌬MEK1:ER-responsive cells were producing autocrine cytokine after ⌬MEK1:ER activation while the IL-3-dependent cells did not.
MEK1 activation suppresses apoptosis in MEK1-responsive FL/⌬MEK1:ER cells
The Raf/MEK/ERK pathway has been linked to the prevention of apoptosis in hematopoietic cells. 3 In order to determine if activation of ⌬MEK1:ER could prevent apoptosis, low molecular weight DNA was prepared from cells grown for 1 day under the indicated conditions ( Figure 5 ). In these experiments, the presence of an apoptotic DNA ladder indicates that the cells have undergone apoptosis, whereas the absence of an apoptotic ladder suggests that the cells have not undergone apoptosis. When the IL-3-dependent cell lines: FL5.12 ( Figure  5, lanes 1 and 3) or FL/⌬MEK1:ER(IL3)Pool 1 ( Figure 5 , lanes 4 and 6) were cultured in the absence of IL-3, the cells underwent apoptosis. In contrast, when the same cells were cultured in IL-3 the cells did not undergo apoptosis ( Figure 5,  lanes 2 and 5) .
Interestingly, when the MEK1-responsive FL/⌬MEK1: ER(Est)c1 cells were cultured for 24 to 48 h in the absence of IL-3 or ␤-estradiol the cells underwent apoptosis ( Figure 5 , lanes 7 and 10). However, when these cells were cultured with either IL-3 (lanes 8 and 11) or ␤-estradiol (lanes 9 and 12), the cells did not undergo apoptosis ( Figure 5 ). Similar results were obtained when 4-HT was used in place of ␤-estradiol (data not presented). Thus, ⌬MEK1:ER activation prevented the appearance of an apoptotic DNA ladder in the MEK1-responsive cells in the absence of IL-3.
To better understand the interaction of ⌬MEK1:ER with the suppression of apoptosis, annexin V/propidium iodide binding analysis was performed. This method allowed for examination of an early event of apoptosis, the exposure of phosphatidylserine to the extracellular environment. By measuring the ability of annexin V to bind exposed phosphatidylserine it could be determined whether the cells were undergoing apoptotic cell death or whether they were resistant to apoptotic stimuli. Cytokine-dependent and MEK1-responsive FL5.12 cells were cultured in the absence of cytokine and ␤-estradiol or in the presence of cytokine or ␤-estradiol for 24-72 h ( Figure 6 ). As compared to the parental FL5.12 cell line, where 
Autocrine GM-CSF expression in ⌬MEK1:ERresponsive cells
To examine whether MEK1 induced an autocrine growth component, the presence of autocrine cytokine expression was examined in the cytokine-dependent and ⌬MEK1:ERresponsive cells by reverse transcriptase PCR (RT-PCR). GM-CSF cDNAs were observed in the ⌬MEK1:ER-responsive FL/⌬MEK1:ER cells, but were not detected in the cells which remained cytokine-dependent (Figure 7) . These cDNAs were verified as GM-CSF by Southern blotting and use of a fulllength GM-CSF probe (data not shown). Thus a consequence to growth in response to activated MEK1 was the synthesis of autocrine cytokine. As a control, the presence of GM-CSF and IL-3 cDNAs were examined in the EL4 thyoma cell line. Upon exposure of this T cell line to phorbol esters, the levels of GM-CSF and IL-3 cDNA detected increased.
Expression of IL-3/GM-CSF receptors on FL5.12 cells
The murine FL5.12 cell line was initially reported as an IL-3-dependent cell line, but the data from the MEK1-responsive Leukemia cells suggested a role for autocrine GM-CSF production in the transformation of these cells. 5 Moreover, the studies on the FL5.12 line were initially performed before rGM-CSF was commercially available and prior to the isolation of monoclonal antibodies (MoAbs) to GM-CSF receptor chains. In order to determine if MEK1-responsive and cytokine-dependent FL5.12 cells had the capability to respond to the autocrine GM-CSF produced in the MEK1-responsive FL5.12 cells, the presence of GM-CSF receptors on cytokine-dependent and MEK1-responsive cells were examined (Figure 8 ). Parental FL5.12, FL/⌬MEK1:ER(IL3)Pool and FL/⌬MEK1: ER(Est)c1 cells were first immunolabeled with antibody to IL-3R␣ (rabbit IgG), GM-CSFR␣ (rabbit IgG), ␤ c (rat IgG) or unlabeled as a control. All the cells were then labeled with a secondary antibody, either a FITC conjugated anti-rabbit IgG or a FITC conjugated anti-rat IgG. The mean fluorescence of the cells was then determined to ascertain the level of expression of the particular subunits of the IL-3 and GM-CSF receptors. In parental FL5.12 cells, the mean fluorescence for each of the receptor subunits was in the mid to upper teens when the cells were cultured in the absence of IL-3. IL-3 was able to increase the mean fluorescence of each of the subunits ( Figure  8a and data not shown) .
The mean fluorescence of the FL/⌬MEK1:ER(IL3)Pool cells was unlike that observed in the parental cell line. Like the parental cells, FL/⌬MEK1:ER(IL3)Pool cells had a low mean fluorescence when analyzing the expression of the ␤ c subunit (Figure 8b ). The mean fluorescence did not vary significantly for the ␤ c subunit in response to IL-3 or ␤-estradiol. In contrast to the parental cells, the mean fluorescence of both IL-3R␣ and GM-CSFR␣ subunits was greatly enhanced. Treatment of these cells with IL-3 lowered the mean fluorescence of IL-3R␣
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Figure 5
Prevention of apoptosis in ⌬MEK1:ER-infected FL5.12 cells. Low molecular weight DNA was prepared from the indicated cell lines that had been grown in the indicated conditions for 1 or 2 days and electrophoresed on 1.5% agarose gels. These experiments were repeated two to six times and similar results were observed with the different cell lines. The presence (+) or absence (−) of IL-3 or ␤-estradiol is indicated. but slightly raised the mean fluorescence of GM-CSFR␣. On the other hand, ␤-estradiol treatment of the FL/⌬MEK1: ER(IL3)Pool cells resulted in a slightly raised mean fluorescence of both IL-3R␣ and GM-CSFR␣ (data not shown). We have previously observed that the presence and absence of cytokine can modulate the expression of the cytokine receptor genes in these cells. ation assays were performed using the FL5.12 parental cell line ( Figure 9 ). These cells were either treated with recombinant GM-CSF, IL-3, IL-4 or filter sterilized supernatant from FL/⌬MEK1:ER(Est)c1 cells, WEHI-3B conditioned medium (as a source of IL-3) or ␤-estradiol. The observed [
3 H]-thymidine counts in the presence of GM-CSF were at least twice those observed when the cells were cultured in IL-4 or ␤-estradiol and not significantly different from counts observed with IL-3 (Figure 9a and c) . In addition, the presence of supernatant from FL/⌬MEK1:ER(Est)c1 cells promoted [ 3 H]-thymidine incorporation, as well as recombinant GM-CSF and IL-3, while ␤-estradiol did not (Figure 9b and c) .
The significance of this autocrine GM-CSF to FL/⌬MEK1: ER(Est)c1 cells was assayed after treatment of these cells with ␤-estradiol and ␣GM-CSF, ␣IL-3 and ␣IGF-1R␣ antibodies (Figure 9d ). The amount of [ 3 H]-thymidine uptake in control untreated cells was normalized to 100% (lane 1). Addition of the ␣GM-CSF antibody to the media greatly inhibited MEK1- 
Autocrine GM-CSF promotes the viability of FL5.12 cells
The FL5.12 cell line has been reported as dependent on the presence of IL-3 for its sustained growth, but since these cells express GM-CSF receptors (both GM-CSFR␣ and ␤ c subunits) that could mediate at least a partial response to GM-CSF, we wished to determine what advantage or effect the autocrine synthesis of GM-CSF would have on these cells by using MTT viability assays (Figure 10 ). Parental FL5.12, FL/⌬MEK1: ER(Est)c1, cells were cultured for 24-48 h in three-fold serial dilutions of phenol-red free RPMI containing IL-3 or GM-CSF. It was determined that although GM-CSF could not protect the FL5.12 cells as well as IL-3, there was an enhancement of viability of these cells in the presence of GM-CSF (Figure 10a  and b) . Likewise, GM-CSF enhanced the viability of the 
Discussion
One of the goals of this study was to investigate the effects of deregulated MEK1 activity on the cytokine dependency of , respectively. 58 The reasons responsible for the differences in recovery of MEK1-responsive cells from the FDC-P1, FL5.12 and TF-1 cell lines are unknown. These cell lines may differ in the expression of growth regulatory proteins which allow certain lines to become more readily transformed to cytokine independence by ⌬MEK1:ER than others. This component could be downstream of MEK1 or possibly an inability of autocrine growth factor to adequately signal through a given cytokine receptor. Moreover, the TF-1 and FDC-P1 cell lines may be more prone to lose tumor suppressor genes or other genes which permit them to grow in response to ⌬MEK1:ER activation.
The ⌬MEK1:ER oncoprotein was required for growth of the MEK1-responsive cells as ␤-estradiol was necessary for cell growth and [
3 H]-thymidine incorporation. ␤-Estradiol treatment of ⌬MEK1:ER-infected cells led to increased ERK2 activity in these cells. The multi-phasic response of ERK2 to ⌬MEK1:ER activation are suggestive of an autocrine component. It will be relevant to determine which downstream targets of MEK1 are abnormally activated in cells which grow in response to ⌬MEK1:ER. ERK2 activity in the MEK1-responsive FL5.12 cells was sustained longer than in the cytokine-dependent ⌬MEK1:ER-infected FL5.12 cells which may explain the ability of the MEK1-responsive cells to grow in response to MEK1 activation. Further analysis of the ⌬MEK1:ER-regulated intracellular signaling pathways in these cells may provide clues to the nature of the differences between responsive and non-responsive cells.
It was apparent that in the MEK1-responsive cells, MEK1 activation was sufficient to suppress apoptosis and promote the entrance of cells into the cell cycle. It was observed that the MEK1-responsive FL5.12 cells were more viable and showed lower levels of annexin V staining and apoptotic DNA fragmentation in response to starvation as compared to the cytokine-dependent cells. One possible explanation of these results is that the MEK1-responsive cells contain a secondary alteration of an apoptotic regulatory protein that promotes the suppression of apoptosis. This alteration in conjunction with MEK1 activation may allow for the transformation of these FL5.12 cells.
Additionally, MEK1 activation in only the MEK1-responsive FL5.12 cells was able to induce entry into S phase. In contrast,
Figure 10
GM-CSF supports FL5.12 viability. The ability of GM-CSF to enhance cytokine-dependent and cytokine-independent FL5.12 viability was assayed by titering IL-3 () and GM-CSF (̆) on to FL5.12 (a and b), FL/⌬MEK1:ER(Est)c1 (c and d) cells. The ability of these cells to utilize MTT over a 2-day period was determined. The level of absorbance at 540 nm was proportional to the viability of the particular cells.
MEK1 activation in some cytokine-dependent FD/⌬MEK1:ER was able to induce entry into S phase but was unable to induce the entry into G 2 /M (data not shown). The percentage of MEK1-responsive FL5.12 cells induced to enter S phase in response to MEK1 activation was less than that induced by IL-3 and took twice as long to reach the same percentage. It is likely that the reduced rate of entry into S phase occurs due to a lag time between MEK1-activation and the resulting synthesis of sufficient levels of autocrine GM-CSF.
As was found in fibroblast models, aberrant activation of the Raf/MEK/MAPK pathway in hematopoietic cells resulted in the secretion of an autocrine growth factor. 8, 65 Cells that were MEK1-responsive were found to express GM-CSF mRNA transcripts. The level of GM-CSF secreted by these cells was sufficient to promote the growth and survival of the parental cells. It is likely that the activation of ⌬MEK1:ER in the MEK1-responsive cells and the subsequent activation of the MAP kinases, ERK1 and ERK2, result in the activation of transcription factors such as Elk-1 and CREB, as well as the activation of additional pathways and transcription factors. These transcription factors may mediate the upregulation of GM-CSF transcription and possibly enhance GM-CSF mRNA stability. In addition, these transcription factors may influence the expression of other growth factors which synergize with GM-CSF to promote MEK1-responsive growth.
These results suggest that there is a relatively rare subset of FL5.12 cells which are susceptible to abrogation of cytokine dependency by ⌬MEK1:ER oncoproteins. Although these abrogation events may not occur in all hematopoietic cells lines, it is relevant to follow in the FL5.12 line, since abrogation of cytokine dependency has been frequently linked to Leukemia malignant transformation. 7, [9] [10] [11] [12] Perkins et al 57 showed that expression of activated MEK1, ⌬MEK1, was unable to relieve the cytokine dependence of the BAF/3 lymphoid precursor cell line, although ⌬MEK1 did suppress apoptosis. Likewise, aberrant ⌬MEK1:ER expression did not readily abrogate the cytokine dependency of the lymphoid precursor FL5.12 cell line.
